Eurogentec to sell majority stake to Kaneka

Eurogentec has agreed a deal with the chemical company Kaneka, which will see the firm become Eurogentec’s majority stakeholder.

The agreement will allow Eurogentec to strengthen its investments in various life science research projects, while also allowing Kaneka to expand its presence in the fields of genomics, proteomics, and biologics.

Jean-Pierre Delwart, chief executive officer of Eurogentec, will remain employed by the company and will play a major role in its integration with Kaneka, while the Delwart Family will stay on the Board of Directors as a minority shareholder.

Mr Delwart expressed confidence that the deal will allow the science company to improve its standing in research fields such as biopharmaceuticals and diagnostics.

He said: “It is essential that we leverage on our strengths and further reinforce our presence as a supplier of innovative products and services. Joining forces with Kaneka will enable us to accelerate our research and developments.”

Eurogentec has been in existence since 1985 and recently expanded its global reach with the acquisition of US-based life sciences firm AnaSpec.